Clinical Trial

MHB018A Treatment in Patients With Active Thyroid Eye Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-19; most recent amendment 2026-03-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-16
Trial Details
NCT Number NCT06989918
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Thyroid Associated Ophthalmopathies
Enrollment 108 participants
Start Date 2025-07-22
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-02